Product Pipeline

Innovative and diverse programs

Our pipeline covers both pharmaceutical and consumer product applications for disease treatment, disease interception and disease prevention.

Microbiome Therapeutics Pipeline
Microbiome Pharmaceuticals Discovery
PHARMA

Lead program aimed at Inflammatory Bowel Diseases. Discovery programs in Spondylarthritis and neurological disorders. Program in metabolic diseases with DuPont.

Microbiome OTC Nutrition Probiotics
OTC / MEDICAL NUTRITION

Specific formulation of two unique strains aimed at Irritable Bowel Syndrome. Research ongoing in a number of therapeutic areas.

Consumer Probiotics Microbiome Nutritional Therapies
CONSUMER

Gut barrier function and antioxidant (PD01); available for licensing. Immune function and gut health (PD12); some geographies already partnered.



A Microbiome Centre of Excellence

Our history goes back to 2008 as a spin-off from Ghent University. We are specialists in gut microbiology and host-microbiome interactions. We have unique proprietary models to study the human and animal intestine in health and disease and our discovery programs can expand to a number of therapeutic areas.

We are happy to collaborate with pharmaceutical and consumer health companies in developing novel products based on our microbiome expertise.

Contact us